Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives.
about
Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South AfricaOral contraceptive use before first birth and risk of breast cancer: a case control studyProgestin and breast cancer. The missing pieces of a puzzle.Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.[Hormonal contraception and breast cancer risk].Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study.Risk factors of breast cancer: a systematic review and meta-analysis.Change in mammographic breast density associated with the use of Depo-Provera.A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium.Progestin and breast cancer risk: a systematic review.Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of ageContraception for cancer survivors.Hormonal contraceptive use and breast cancer in Thai women.Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review.Hormonal contraception and breast cancer, what more do we need to know?Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.Regulation of Msx2 gene expression by steroid hormones in human nonmalignant and malignant breast cancer explants cultured in vitro.Assessing the Role of Reversible Contraceptives in the Health Care of Women as it Pertains to Cancer Prevention.Cancer in Africa: a preventable public health crisis
P2860
Q24799665-5643B159-8FDC-48CC-8AC2-E3E6827640D2Q24800615-1F2D6EB6-D6C2-4368-8866-F7E67EFA0286Q33345732-EE6CD772-4CC9-4CA9-865A-3D0C55DD30E3Q33655313-03DF5A6A-2456-4119-B499-96632E383B7BQ34057842-042798A5-B97E-48FB-8FCD-E4DD8B6A1CA6Q34131588-0FC6D4E4-71A5-4524-97B0-46D2A1EB8A49Q34192784-34729EE5-525E-4EC0-B7AD-58DCD4A4545AQ34346863-3C98C376-D66E-4283-97FE-8BC8E212A5BCQ35170956-A75F5276-BBC2-4323-ADAB-8C95E03A9E19Q35174900-28D8AD2C-9842-487F-9686-164AFE2CFC34Q35877473-95B7AE4B-32B6-4FDC-BAED-7AD1AC3B6BE5Q35894901-080B1260-E671-4539-B72B-7D170E7FBFE8Q37390053-00503C3A-3C9B-4CC1-BD22-EB5001A177DFQ37725165-CC220A0A-B797-4CBF-AF49-38872BE0897CQ38538492-359260BB-F93F-4CE9-B38F-BE74F1254F10Q38714408-47A65A1E-CB82-43C3-8B04-8FCE891C407BQ44191663-8827C8DA-A0B0-4227-A8FC-DFE335B955E8Q46536364-1C741970-155A-4986-879D-8799E6904A60Q47612930-95B7E5B0-C08F-48EA-992C-673EDF3C715CQ57251784-54DC2424-4A2C-408F-8E80-2F9612407CB8
P2860
Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@en
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@nl
type
label
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@en
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@nl
prefLabel
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@en
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@nl
P2093
P1476
Risk of breast cancer in relat ...... en/progestogen contraceptives.
@en
P2093
Katzenellenbogen J
P304
P356
10.1093/OXFORDJOURNALS.AJE.A010219
P407
P577
2000-02-01T00:00:00Z